牛牛AI助手已提取核心信息
Capital International Investors (CII), a division of Capital Research and Management Company, has filed an amended Schedule 13G with the United States Securities and Exchange Commission on February 7, 2024, indicating a significant stake in CRISPR Therapeutics AG. The filing, dated December 29, 2023, shows that CII has beneficial ownership of 6,420,736 shares of CRISPR Therapeutics' common stock, representing 8.1% of the company's class of securities believed to be outstanding. The shares are held in the ordinary course of business, with no intention of influencing the control of the issuer. CII has sole voting power over 6,374,948 shares and sole dispositive power over all 6,420,736 shares, with no shared voting or dispositive power reported.
Capital International Investors (CII), a division of Capital Research and Management Company, has filed an amended Schedule 13G with the United States Securities and Exchange Commission on February 7, 2024, indicating a significant stake in CRISPR Therapeutics AG. The filing, dated December 29, 2023, shows that CII has beneficial ownership of 6,420,736 shares of CRISPR Therapeutics' common stock, representing 8.1% of the company's class of securities believed to be outstanding. The shares are held in the ordinary course of business, with no intention of influencing the control of the issuer. CII has sole voting power over 6,374,948 shares and sole dispositive power over all 6,420,736 shares, with no shared voting or dispositive power reported.
资本研究与管理公司旗下的资本国际投资者（CII）已于2024年2月7日向美国证券交易委员会提交了经修订的附表13G，表示持有CRISPR Therapeutics AG的大量股份。这份日期为2023年12月29日的文件显示，CII拥有CRISPR Therapeutics普通股的6,420,736股实益所有权，占该公司据信已发行证券类别的8.1％。股票在正常业务过程中持有，无意影响发行人的控制权。CII拥有对6,374,948股股票的唯一投票权，对所有6,420,736股股票拥有唯一的处置权，没有报告共享投票权或处置权。
资本研究与管理公司旗下的资本国际投资者（CII）已于2024年2月7日向美国证券交易委员会提交了经修订的附表13G，表示持有CRISPR Therapeutics AG的大量股份。这份日期为2023年12月29日的文件显示，CII拥有CRISPR Therapeutics普通股的6,420,736股实益所有权，占该公司据信已发行证券类别的8.1％。股票在正常业务过程中持有，无意影响发行人的控制权。CII拥有对6,374,948股股票的唯一投票权，对所有6,420,736股股票拥有唯一的处置权，没有报告共享投票权或处置权。
有用
没用